Actively Recruiting
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
Led by Ruijin Hospital · Updated on 2024-08-02
50
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
S
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lung cancer is one of the most common malignant tumors worldwide and has the highest mortality rate among malignant tumors. In recent years, with the gradual development of therapeutic modalities such as targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, late tumor staging at the time of diagnosis often leaves patients with only pneumonectomy, which affects the prognosis with a higher rate of postoperative complications than lobectomy, poorer quality of life and the possible loss of the opportunity to continue adjuvant therapy. Our group proposes to conduct this single-arm prospective clinical study to investigate the feasibility, safety and prognosis of the conversion from pneumonectomy to lobectomy after neoadjuvant or induction therapy in patients with operable non-small cell lung cancer.
CONDITIONS
Official Title
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who voluntarily agree to participate, can follow study requirements, and sign consent
- Age between 18 and 75 years old, any gender
- Pathologically confirmed non-small cell lung cancer, clinical stage T2-4N0-2, operable and potentially requiring pneumonectomy
- ASA physical status classification of Grade I to III
- Cardiopulmonary function suitable for radical lung cancer surgery; normal liver and kidney function
You will not qualify if you...
- Serious heart, lung, liver, or kidney dysfunction preventing surgery tolerance
- Uncontrolled neurological or psychiatric disorders affecting compliance or treatment reporting
- Scheduled for emergency or palliative surgery due to lung abscess or bleeding
- Previously treated with or currently receiving neoadjuvant or induction radiotherapy or targeted therapy
- History of other malignancies
- Past thoracic surgery
- Pregnant or breastfeeding women
- Women of childbearing age who refuse to use contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hospital
Shanghai, China, 200025
Actively Recruiting
Research Team
H
Hecheng Li
CONTACT
Z
Zhengxin Yin
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here